Why now is a good time to invest in European markets

(Image credit: Getty Images)

published 6 June 2024

“After a decade of stunning performance” on Wall Street, global investors are feeling uneasy about the dominance of US stocks in their portfolios, says Sharon Bell in the Financial Times. European equities could offer better value. The energy shock has made the last few years a tricky period for European markets, opening a large transatlantic valuation gap. US shares trade on a price/earnings ratio of over 21, compared with 14 in Europe and around 12 in the UK.

European stocks have at least managed to hold their own this year, says Bastien Bouchaud in Les Echos. The Euro Stoxx 50 index has gained nearly 12% so far in 2024, just a smidge behind the S&P 500. Inflation has cooled faster on the “old continent” than in the US, with the European Central Bank poised to start cutting interest rates as early as June. Easier money usually finds its way into financial markets, which will support share valuations.

Much as US markets have been driven by the “Magnificent Seven” tech firms, so too a handful of European giants have made the running. Dutch chip specialist ASML has accounted for about a fifth of the Euro Stoxx 50’s gains this year alone. Bank Société Générale has dubbed the outperformers the “Seven Wonders of Europe”, says Jamie Chisholm in MarketWatch. The group includes ASML, pharma group Novo Nordisk, luxury conglomerates LVMH and Hermès, software play SAP and industrials Siemens and Schneider Electric. Many of them also feature in Goldman Sachs’ “Granolas” category, a pan-European grouping of 11 top stocks that also includes UK firms AstraZeneca and GSK.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

The Granolas make up about a quarter of the Stoxx 600 market and contributed 60% of the gain in the year to 1 March, says Michael Fahy in Investors’ Chronicle. The group collectively trades at a roughly 60% valuation premium to the wider European market, but is still on a discount of 30% to the Magnificent Seven. Over three years they’ve broadly “matched the returns of the US tech giants”, but with less volatility. No European firms rise to the trillion-dollar valuations of the biggest US companies, says Jocelyn Jovène for Morningstar. But the Granolas do represent a more diversified grouping than the US tech giants, taking in healthcare, technology and both cyclical and defensive consumer themes.

European stock markets have transformed over the past decade, says Frédérique Carrier of RBC Wealth Management. No longer the preserve of stodgy banks and telecom groups, today's fast-growing technology, healthcare, industrials and consumer discretionary firms together account for 57% of the MSCI Europe ex-UK index, up from 37% in 2011. “Bloated conglomerates” have slimmed down into leaner operators: return on equity rose from 9.8% in 2011 to 13% last year. Europe may lack the dynamism of the US or emerging economies, but investors often overlook the fact that about 55% of revenue comes from outside Europe. “No longer wan and listless... European equities are emerging from their chrysalis with newfound potential.”

Alex is an investment writer who has been contributing to MoneyWeek since 2015. He has been the magazine’s markets editor since 2019.

Alex has a passion for demystifying the often arcane world of finance for a general readership. While financial media tends to focus compulsively on the latest trend, the best opportunities can lie forgotten elsewhere.

He is especially interested in European equities – where his fluent French helps him to cover the continent’s largest bourse – and emerging markets, where his experience living in Beijing, and conversational Chinese, prove useful.

Hailing from Leeds, he studied Philosophy, Politics and Economics at the University of Oxford. He also holds a Master of Public Health from the University of Manchester.